Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

ABCL AbCellera Biologics Inc

Price (delayed)

$2.05

Market cap

$611.89M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.56

Enterprise value

$490.84M

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners ...

Highlights
The company's quick ratio rose by 23% YoY
AbCellera Biologics's debt has decreased by 7% YoY but it has increased by 4.1% from the previous quarter
The company's revenue fell by 35% YoY and by 20% QoQ
The gross profit has contracted by 35% YoY and by 20% from the previous quarter

Key stats

What are the main financial stats of ABCL
Market
Shares outstanding
298.48M
Market cap
$611.89M
Enterprise value
$490.84M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.6
Price to sales (P/S)
26.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
21.23
Earnings
Revenue
$23.12M
Gross profit
$23.12M
Operating income
-$322.53M
Net income
-$167.87M
EBIT
-$210.63M
EBITDA
-$113.8M
Free cash flow
-$143.29M
Per share
EPS
-$0.56
EPS diluted
-$0.56
Free cash flow per share
-$0.48
Book value per share
$3.43
Revenue per share
$0.08
TBVPS
$4.22
Balance sheet
Total assets
$1.34B
Total liabilities
$321.23M
Debt
$63.21M
Equity
$1.02B
Working capital
$689.58M
Liquidity
Debt to equity
0.06
Current ratio
10.15
Quick ratio
8.89
Net debt/EBITDA
1.06
Margins
EBITDA margin
-492.3%
Gross margin
100%
Net margin
-726.2%
Operating margin
-1,395.3%
Efficiency
Return on assets
-12.2%
Return on equity
-15.7%
Return on invested capital
-19.3%
Return on capital employed
-16.6%
Return on sales
-911.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ABCL stock price

How has the AbCellera Biologics stock price performed over time
Intraday
-2.38%
1 week
1.99%
1 month
-15.98%
1 year
-46.34%
YTD
-30.03%
QTD
-8.07%

Financial performance

How have AbCellera Biologics's revenue and profit performed over time
Revenue
$23.12M
Gross profit
$23.12M
Operating income
-$322.53M
Net income
-$167.87M
Gross margin
100%
Net margin
-726.2%
AbCellera Biologics's operating margin has shrunk by 120% YoY and by 28% QoQ
AbCellera Biologics's net margin has plunged by 77% YoY and by 29% from the previous quarter
ABCL's operating income is down by 42% year-on-year and by 2.5% since the previous quarter
The company's revenue fell by 35% YoY and by 20% QoQ

Price vs fundamentals

How does ABCL's price correlate with its fundamentals

Growth

What is AbCellera Biologics's growth rate over time

Valuation

What is AbCellera Biologics stock price valuation
P/E
N/A
P/B
0.6
P/S
26.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
21.23
ABCL's EPS is down by 8% YoY
ABCL's P/B is 81% below its 5-year quarterly average of 3.2 and 14% below its last 4 quarters average of 0.7
The equity has declined by 9% year-on-year and by 3.1% since the previous quarter
The P/S is 37% more than the 5-year quarterly average of 19.3 but 2.6% less than the last 4 quarters average of 27.1
The company's revenue fell by 35% YoY and by 20% QoQ

Efficiency

How efficient is AbCellera Biologics business performance
ABCL's ROS has plunged by 93% YoY and by 31% from the previous quarter
The company's return on invested capital fell by 27% YoY and by 6% QoQ
AbCellera Biologics's ROE has decreased by 25% YoY and by 5% from the previous quarter
The ROA has contracted by 24% YoY and by 5% from the previous quarter

Dividends

What is ABCL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ABCL.

Financial health

How did AbCellera Biologics financials performed over time
ABCL's current ratio is up by 31% YoY and by 3.5% QoQ
The company's quick ratio rose by 23% YoY
AbCellera Biologics's debt is 94% less than its equity
The equity has declined by 9% year-on-year and by 3.1% since the previous quarter
AbCellera Biologics's debt has decreased by 7% YoY but it has increased by 4.1% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.